Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials
Author:
Funder
F. Hoffmann-La Roche
F. Hoffmann-La Roche Ltd
Publisher
Elsevier BV
Subject
General Biochemistry, Genetics and Molecular Biology,General Medicine
Reference27 articles.
1. Multiple sclerosis;Reich;N Engl J Med,2018
2. Phases and phenotypes of multiple sclerosis;Kantarci;Continuum (Minneap Minn),2019
3. Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials;Kappos;JAMA Neurol,2020
4. Silent progression in disease activity-free relapsing multiple sclerosis;Cree;Ann Neurol,2019
5. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis;Hauser;N Engl J Med,2017
Cited by 25 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. MultiSCRIPT-Cycle 1—a pragmatic trial embedded within the Swiss Multiple Sclerosis Cohort (SMSC) on neurofilament light chain monitoring to inform personalized treatment decisions in multiple sclerosis: a study protocol for a randomized clinical trial;Trials;2024-09-11
2. Association between cadmium exposure and serum neurofilament light chain levels: A nationwide population-based survey;Ecotoxicology and Environmental Safety;2024-09
3. Neurofilament Light Chain Serum Levels Mirror Age and Disability in Secondary Progressive Multiple Sclerosis;Neurology Neuroimmunology & Neuroinflammation;2024-09
4. Fluid biomarkers in multiple sclerosis: from current to future applications;The Lancet Regional Health - Europe;2024-09
5. Primary Progressive Multiple Sclerosis—A Key to Understanding and Managing Disease Progression;International Journal of Molecular Sciences;2024-08-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3